Tiger team: a panel of human neutralizing mAbs targeting SARS-CoV-2 spike at multiple epitopes
T Noy-Porat, E Makdasi, R Alcalay, A Mechaly, Y Levy… - bioRxiv, 2020 - biorxiv.org
The novel highly transmissible human coronavirus SARS-CoV-2 is the causative agent of
the COVID-19 pandemic. Thus far, there is no approved therapeutic drug, specifically …
the COVID-19 pandemic. Thus far, there is no approved therapeutic drug, specifically …
Development and structural basis of a two-MAb cocktail for treating SARS-CoV-2 infections
The ongoing pandemic of coronavirus disease 2019 (COVID-19) is caused by severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2). Neutralizing antibodies against SARS …
respiratory syndrome coronavirus 2 (SARS-CoV-2). Neutralizing antibodies against SARS …
A panel of human neutralizing mAbs targeting SARS-CoV-2 spike at multiple epitopes
T Noy-Porat, E Makdasi, R Alcalay, A Mechaly… - Nature …, 2020 - nature.com
The novel highly transmissible human coronavirus SARS-CoV-2 is the causative agent of
the COVID-19 pandemic. Thus far, there is no approved therapeutic drug specifically …
the COVID-19 pandemic. Thus far, there is no approved therapeutic drug specifically …
[PDF][PDF] Potent neutralizing monoclonal antibodies directed to multiple epitopes on the SARS-CoV-2 spike
Abstract 23 The SARS-CoV-2 pandemic rages on with devasting consequences on human
lives and the 24 global economy. The discovery and development of virus-neutralizing …
lives and the 24 global economy. The discovery and development of virus-neutralizing …
An in vitro experimental pipeline to characterize the binding specificity of SARS-CoV-2 neutralizing antibodies
KE Atanasoff, L Brambilla, DC Adelsberg, S Kowdle… - bioRxiv, 2023 - biorxiv.org
Abstract The coronavirus disease 2019 (COVID-19) pandemic caused by the severe acute
respiratory syndrome-coronavirus-2 (SARS-CoV-2) has led to over 760 million cases and> …
respiratory syndrome-coronavirus-2 (SARS-CoV-2) has led to over 760 million cases and> …
An in vitro experimental pipeline to characterize the epitope of a SARS-CoV-2 neutralizing antibody
KE Atanasoff, L Brambilla, DC Adelsberg, S Kowdle… - Mbio, 2024 - Am Soc Microbiol
ABSTRACT The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute
respiratory syndrome-coronavirus-2 (SARS-CoV-2) has led to over 770 million cases and> …
respiratory syndrome-coronavirus-2 (SARS-CoV-2) has led to over 770 million cases and> …
Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domain
Potent neutralizing monoclonal antibodies are one of the few agents currently available to
treat COVID-19. SARS-CoV-2 variants of concern (VOCs) that carry multiple mutations in the …
treat COVID-19. SARS-CoV-2 variants of concern (VOCs) that carry multiple mutations in the …
Antibodies that neutralize all current SARS-CoV-2 variants of concern by conformational locking
SUMMARY SARS-CoV-2 continues to evolve and evade most existing neutralizing
antibodies, including all clinically authorized antibodies. We have isolated and …
antibodies, including all clinically authorized antibodies. We have isolated and …
[HTML][HTML] Synthetic repertoires derived from convalescent COVID-19 patients enable discovery of SARS-CoV-2 neutralizing antibodies and a novel quaternary binding …
J Goike, CL Hsieh, A Horton, EC Gardner, F Bartzoka… - Biorxiv, 2021 - ncbi.nlm.nih.gov
The ongoing evolution of SARS-CoV-2 into more easily transmissible and infectious variants
has sparked concern over the continued effectiveness of existing therapeutic antibodies and …
has sparked concern over the continued effectiveness of existing therapeutic antibodies and …
A potent human monoclonal antibody with pan-neutralizing activities directly dislocates S trimer of SARS-CoV-2 through binding both up and down forms of RBD
X Wang, A Hu, X Chen, Y Zhang, F Yu, S Yue… - … and Targeted Therapy, 2022 - nature.com
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a global
pandemic of novel coronavirus disease (COVID-19). The neutralizing monoclonal …
pandemic of novel coronavirus disease (COVID-19). The neutralizing monoclonal …